SOURCE: Streetwise Reports

Streetwise Reports

June 16, 2016 09:00 ET

Soligenix Develops Defenses Against Bioterrorism

SAN FRANCISCO, CA--(Marketwired - June 16, 2016) - Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company.

Included in this article is: Soligenix Inc. (OTCQB: SNGX)

Soligenix Inc. reported Q1/16 results with total revenues of $2.6M, including contract revenues from BARDA (Biomedical Advanced Research and Development Authority) and NIAID (National Institute of Allergy and Infectious Diseases) for development of OrbeShield and ThermoVax combined with RiVax. Net loss for the quarter was $1.1M or $(0.04) per share and the company ended the period with $4.3M in cash.

The company released positive data from the Phase 2 oral mucositis study with SGX942 this past quarter. SGX942's novel mechanism of action as an Innate Defense Regulator showed the potential to address all stages of oral mucositis disease progression. The company is currently in talks with the US and EU regulatory authorities and expects to initiate a pivotal Phase 2b/3 study before the year-end.

Continue reading this article: Soligenix Develops Defenses Against Bioterrorism

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

Editor's Note: This article has been excerpted from a Maxim Group research report. Click here to read the entire report.


Soligenix Inc. is a sponsor of Streetwise Reports. Soligenix Inc. was not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information